The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder
Open accessAbstract
Importance: Opioid overdose deaths in the United States continue to increase, reflecting a growing need to treat those with opioid use disorder (OUD). Little is known about counties with high rates of opioid overdose mortality but low availability of OUD treatment. Objective: To identify characteristics of US counties with persistently high rates of opioid overdose mortality and low capacity to deliver OUD medications. Design, Setting, and Participants: In this cross-sectional study of data from 3142 US counties from January 1, 2015, to December 31, 2017, rates of opioid overdose mortality were compared with availability in 2017 of OUD medication providers (24 851 buprenorphine-waivered clinicians [physicians, nurse practitioners, and physician assistants], 1517 opioid treatment programs [providing methadone], and 5222 health care professionals who could prescribe extended-release naltrexone). Statistical analysis was performed from April 20, 2018, to May 8, 2019. Exposures: Demographic, workforce, lack of insurance, road density, urbanicity, opioid prescribing, and regional division county-level characteristics. Main Outcome and Measures: The outcome variable, "opioid high-risk county," was a binary indicator of a high (above national) rate of opioid overdose mortality with a low (below national) rate of provider availability to deliver OUD medication. Spatial logistic regression models were used to determine associations with being an opioid high-risk county. Results: Of 3142 counties, 751 (23.9%) had high rates of opioid overdose mortality. A total of 1457 counties (46.4%), and 946 of 1328 rural counties (71.2%), lacked a publicly available OUD medication provider in 2017. In adjusted models, compared with the West North Central division, counties in the East North Central, Mountain, and South Atlantic divisions had increased odds of being opioid high-risk counties (East North Central: odds ratio [OR], 2.21; 95% CI, 1.19-4.12; Mountain: OR, 4.15; 95% CI, 1.34-12.89; and South Atlantic: OR, 2.99; 95% CI, 1.26-7.11). A 1% increase in unemployment was associated with increased odds (OR, 1.09; 95% CI, 1.03-1.15) of a county being an opioid high-risk county. Counties with an additional 10 primary care clinicians per 100 000 population had a reduced risk of being opioid high-risk counties (OR, 0.89; 95% CI, 0.85-0.93), as did counties that were micropolitan (vs metropolitan) (OR, 0.67; 95% CI, 0.50-0.90) and those that had an additional 1% of the population younger than 25 years (OR, 0.95; 95% CI, 0.92-0.98). Conclusions and Relevance: Counties with low availability of OUD medication providers and high rates of opioid overdose mortality were less likely to be micropolitan and have lower primary care clinician density, but were more likely to be in the East North Central, South Atlantic, or Mountain division and have higher rates of unemployment. Strategies to increase medication treatment must account for these factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Increases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,731
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Mortality and Morbidity in the 21st Century
Case, A., & Deaton, A. (2017) · Brookings Papers on Economic Activity · doi:10.1353/eca.2017.0005 · Cited by 1,448
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Opioid crisis: no easy fix to its social and economic determinants
Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018) · American Journal of Public Health · doi:10.2105/ajph.2017.304187 · Cited by 923
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Massachusetts Department of Public Health
Gallagher, S. S., Guyer, B., Kotelchuck, M., Bass, J., Lovejoy, F. H., McLoughlin, E., & Mehta, K. (1982) · New England Journal of Medicine · doi:10.1056/nejm198210143071613 · Cited by 591
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., Davoli, M., & Breen, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209 · Cited by 531
Retention in medication-assisted treatment for opiate dependence: A systematic review
Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016) · Journal of Addictive Diseases · doi:10.1080/10550887.2016.1100960 · Cited by 489
Oral naltrexone maintenance treatment for opioid dependence
Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001333.pub4 · Cited by 419
Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder
Rosenblatt, R. A., Andrilla, C. H. A., Catlin, M., & Larson, E. H. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1735 · Cited by 380
Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., Dackis, C., & O’Brien, C. P. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.210 · Cited by 348
Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019) · The Journal of Rural Health · doi:10.1111/jrh.12307 · Cited by 311
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009
Schwartz, R. P., Gryczynski, J., O’Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., Mitchell, S. G., & Jaffe, J. H. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301049 · Cited by 276
Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States
Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S., Wakeman, S. E., Freedberg, K. A., Raphel, T. J., Knudsen, A. B., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7621 · Cited by 274
County Presidential Election Returns 2000-2024
Lab, M. E. D. A. S. (2025) · Harvard Dataverse · doi:10.7910/dvn/voqchq · Cited by 262
Komaromy, M., Duhigg, D., Metcalf, A., Carlson, C., Kalishman, S., Hayes, L., Burke, T., Thornton, K., & Arora, S. (2016) · Substance Abuse · doi:10.1080/08897077.2015.1129388 · Cited by 258
Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment
Haffajee, R. L., Bohnert, A. S. B., & Lagisetty, P. A. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.12.022 · Cited by 252
Self-citationOpioid agonist treatment for pharmaceutical opioid dependent people
Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011117.pub2 · Cited by 249
Saloner, B., & Karthikeyan, S. (2015) · JAMA · doi:10.1001/jama.2015.10345 · Cited by 226
Degenhardt, L., Larney, S., Kimber, J., Gisev, N., Farrell, M., Dobbins, T., Weatherburn, D. J., Gibson, A., Mattick, R., Butler, T., et al. (2014) · Addiction · doi:10.1111/add.12536 · Cited by 223
Extended‐release injectable naltrexone for opioid use disorder: a systematic review
Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, D. A., Oga, E. A., Bigelow, G. E., & Silverman, K. (2018) · Addiction · doi:10.1111/add.14180 · Cited by 217
Factors Associated With County-Level Differences in U.S. Drug-Related Mortality Rates
Monnat, S. M. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.01.040 · Cited by 215
Tsui, J. I., Evans, J. L., Lum, P. J., Hahn, J. A., & Page, K. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5416 · Cited by 199
Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities
Wakeman, S. E., & Barnett, M. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1802741 · Cited by 175
Primary care models for treating opioid use disorders: What actually works? A systematic review
Lagisetty, P., Klasa, K., Bush, C. A., Heisler, M., Chopra, V., & Bohnert, A. S. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186315 · Cited by 169
Self-citationCorrected US opioid‐involved drug poisoning deaths and mortality rates, 1999–2015
Ruhm, C. J. (2018) · Addiction · doi:10.1111/add.14144 · Cited by 169
Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D., & Stein, B. D. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1205 · Cited by 159
Geographic variation in opioid and heroin involved drug poisoning mortality rates
Ruhm, C. J. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.06.009 · Cited by 152
Supply of buprenorphine waivered physicians: The influence of state policies
Stein, B. D., Gordon, A. J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., LESLIE, D. L., & Sorbero, M. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.010 · Cited by 117
Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., LESLIE, D. L., Sorbero, M., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015) · Milbank Quarterly · doi:10.1111/1468-0009.12137 · Cited by 116
Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment
Stein, B. D., Sorbero, M., Dick, A. W., Pacula, R. L., Burns, R. M., & Gordon, A. J. (2016) · JAMA · doi:10.1001/jama.2016.10542 · Cited by 113
Methadone in Primary Care — One Small Step for Congress, One Giant Leap for Addiction Treatment
Samet, J. H., Botticelli, M. P., & Bharel, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1803982 · Cited by 99
Knudsen, H. K. (2015) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2015.76.644 · Cited by 78
The Untapped Potential of Office-Based Buprenorphine Treatment
Sigmon, S. C. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2421 · Cited by 74
Comparison between buprenorphine provider availability and opioid deaths among US counties
Jones, C. W., Christman, Z., Smith, C. M., Safferman, M. R., Salzman, M., Baston, K., & Haroz, R. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.07.008 · Cited by 72
Geographic Disparities in Availability of Opioid Use Disorder Treatment for Medicaid Enrollees
Abraham, A. J., Andrews, C. M., Yingling, M. E., & Shannon, J. (2017) · Health Services Research · doi:10.1111/1475-6773.12686 · Cited by 70
Langabeer, J. R., Gourishankar, A., Chambers, K. A., Giri, S., Madu, R., & Champagne‐Langabeer, T. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000523 · Cited by 61
Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids
Nielsen, S., Larance, B., & Lintzeris, N. (2017) · JAMA · doi:10.1001/jama.2017.0001 · Cited by 60
Telemedicine’s Role in Addressing the Opioid Epidemic
Yang, Y. T., Weintraub, E., & Haffajee, R. L. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.001 · Cited by 43
Self-citationUse of Opioid Agonist Therapy for Medicare Patients in 2013
Lembke, A., & Chen, J. H. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1390 · Cited by 41
Buprenorphine physician supply: Relationship with state-level prescription opioid mortality
Knudsen, H. K., Havens, J. R., Lofwall, M. R., Studts, J. L., & WALSH, S. L. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.08.642 · Cited by 39
Lowder, E. M., Ray, B. R., Huynh, P., Ballew, A., & Watson, D. P. (2018) · American Journal of Public Health · doi:10.2105/ajph.2018.304683 · Cited by 28
Cited by
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K. M., Jones, C. M., & Cerdá, M. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103786 · Cited by 308
“Recent data show that 46% of counties lack an MOUD medication provider (Haffajee et al., 2019), and 32% have no specialty SUD treatment programs at all (Langabeer et al., 2019).”
Meyerson, B. E., Russell, D. M., Kichler, M., Atkin, T., Fox, G., & Coles, H. B. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103112 · Cited by 99
Projected estimates of opioid mortality after community-level interventions.
Linas, B. P., Savinkina, A., Madushani, R. W. M. A., Wang, J., Eftekhari Yazdi, G., Chatterjee, A., Walley, A. Y., Morgan, J. R., Epstein, R. L., Assoumou, S. A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37259 · Cited by 72
Lo-Ciganic, W.-H., Donohue, J. M., Hulsey, E. G., Barnes, S., Li, Y., Kuza, C. C., Yang, Q., Buchanich, J., Huang, J. L., Mair, C., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0248360 · Cited by 32
Metadata
- Authors
- Haffajee, R. L., Lin, L. A., Bohnert, A. S. B., & Goldstick, J. E.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2019-06-28
- Volume
- 2
- Issue
- 6
- Pages
- e196373
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W2955994854
- Cited by
- 261
- References
- 49
- FWCI
- 30.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.